Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 4/20 | 0.42 |
| ▸ | GHSR | Q92847 | 4/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | GCK | P35557 | 1/20 | 0.41 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30198978 | 0.91 | NR1H2 (0.54) | NR1H2ESR2GHSRMAOBMAOA | |
| SCHEMBL30199514 | 0.91 | NR1H2 (0.54) | NR1H2ESR2GHSRMAOBMAOA | |
| SCHEMBL29097840 | 0.91 | NR1H2 (0.54) | NR1H2ESR2GHSRMAOBMAOA | |
| SCHEMBL5049891 | 0.86 | HRH3 (0.49) | ESR2GHSRMAOBMAOA | |
| SCHEMBL4887148 | 0.83 | KMT2A (0.43) | NR1H2ESR2MMP1ADAM17MMP2 | |
| SCHEMBL30200125 | 0.81 | NR1H2 (0.57) | NR1H2ESR2GHSRMAOBMAOA | |
| SCHEMBL29098082 | 0.81 | NR1H2 (0.57) | NR1H2ESR2GHSRMAOBMAOA | |
| SCHEMBL30199590 | 0.81 | NR1H2 (0.60) | NR1H2ESR2GHSR | |
| SCHEMBL29098066 | 0.81 | NR1H2 (0.53) | NR1H2ESR2GHSRMAOB | |
| SCHEMBL30199457 | 0.81 | NR1H2 (0.53) | NR1H2ESR2GHSRMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504392-B2 | 2,3,4,5-tetrahydro-1H-3-benzazepines and their medical use | GLAXO GROUP LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| US-20050261279-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261279-A1 | Compounds | CBR1, CBR3, OXER1 | NR1H2 72/4885ESR2 54/4885MMP1 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.